基于TDM数据的模型指导剂量个体化中应对个体间变异的方法
本研究以凝血因子VIII群体药动学模型为例,评估基于模型的TDM中处理个体间变异(IOV)的五种方法,并探索IOV幅度和采样次数的影响。结果显示IOV低于IIV时各方法准确性良好但精确度差异大,方法(ii)在广泛情景下最精确。结论是生成EBEs时纳入IOV,但计算未来剂量时排除IOV相关变异部分。
要点
- 推荐在生成EBEs时纳入IOV,但计算个体参数时排除IOV相关变异。
- IOV低于IIV时各方法准确性良好,但精确度随IOV幅度变化大。
- 方法(ii)在稀疏采样或高IOV时最精确,优于体重给药。
核心结论
- 基于所研究情景和理论预期,模型指导剂量个体化中处理IOV的最佳方法是:生成EBEs时纳入IOV,但计算未来剂量所用的个体参数时排除IOV相关变异部分。
研究设计与样本
- 本研究以凝血因子VIII群体药动学模型为例,评估5种基于模型的TDM方法,并探索IOV幅度(0-50%)和 occasion/观察次数的影响,与常规体重给药比较,用预测误差百分位数评估预测性能。
主要发现
- 当IOV低于IIV时,所有方法准确性良好(预测误差第50百分位数[P50]<7.4%),但精确度在不同IOV幅度间差异大(P97.5 61-528%)。
- 方法(ii)在广泛情景下是最精确的预测方法,尤其在稀疏采样或高IOV幅度时。
- 大多数情景下,体重给药的预测精确度低于基于模型的TDM方法。
关键数值与推荐
- IOV低于IIV时,所有方法预测误差第50百分位数(P50)<7.4%。
- 精确度以预测误差第97.5百分位数(P97.5)表示,在不同IOV幅度下范围为61-528%。
临床怎么用
- 临床采用基于模型的TDM进行剂量个体化时,应在贝叶斯估计中纳入IOV,但计算未来剂量时排除IOV相关变异部分,以提高预测精确度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aims to assess approaches to handle interoccasion variability (IOV) in a model-based therapeutic drug monitoring (TDM) context, using a population pharmacokinetic model of coagulation factor VIII as example. METHODS: We assessed 5 model-based TDM approaches: empirical Bayes estimates (EBEs) from a model including IOV, with individualized doses calculated based on individual parameters either (i) including or (ii) excluding variability related to IOV; and EBEs from a model excluding IOV by (iii) setting IOV to zero, (iv) summing variances of interindividual variability (IIV) and IOV into a single IIV term, or (v) re-estimating the model without IOV. The impact of varying IOV magnitudes (0-50%) and number of occasions/observations was explored. The approaches were compared with conventional weight-based dosing. Predictive performance was assessed with the prediction error percentiles. RESULTS: When IOV was lower than IIV, the accuracy was good for all approaches (50th percentile of the prediction error [P50] <7.4%), but the precision varied substantially between IOV magnitudes (P97.5 61-528%). Approach (ii) was the most precise forecasting method across a wide range of scenarios, particularly in case of sparse sampling or high magnitudes of IOV. Weight-based dosing led to less precise predictions than the model-based TDM approaches in most scenarios. CONCLUSIONS: Based on the studied scenarios and theoretical expectations, the best approach to handle IOV in model-based dose individualization is to include IOV in the generation of the EBEs but exclude the portion of unexplained variability related to IOV in the individual parameters used to calculate the future dose.
引用
- Abrantes JA, Jönsson S, Karlsson MO, et al. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol. 2019. PMID: 30767254. doi:10.1111/bcp.13901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。